300 related articles for article (PubMed ID: 30497491)
1. Chemotherapy-driven increases in the CDKN1A/PTN/PTPRZ1 axis promote chemoresistance by activating the NF-κB pathway in breast cancer cells.
Huang P; Ouyang DJ; Chang S; Li MY; Li L; Li QY; Zeng R; Zou QY; Su J; Zhao P; Pei L; Yi WJ
Cell Commun Signal; 2018 Nov; 16(1):92. PubMed ID: 30497491
[TBL] [Abstract][Full Text] [Related]
2. PTN signaling: Components and mechanistic insights in human ovarian cancer.
Sethi G; Kwon Y; Burkhalter RJ; Pathak HB; Madan R; McHugh S; Atay S; Murthy S; Tawfik OW; Godwin AK
Mol Carcinog; 2015 Dec; 54(12):1772-85. PubMed ID: 25418856
[TBL] [Abstract][Full Text] [Related]
3. Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth.
Shi Y; Ping YF; Zhou W; He ZC; Chen C; Bian BS; Zhang L; Chen L; Lan X; Zhang XC; Zhou K; Liu Q; Long H; Fu TW; Zhang XN; Cao MF; Huang Z; Fang X; Wang X; Feng H; Yao XH; Yu SC; Cui YH; Zhang X; Rich JN; Bao S; Bian XW
Nat Commun; 2017 Jun; 8():15080. PubMed ID: 28569747
[TBL] [Abstract][Full Text] [Related]
4. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
Wang P; Hu Y; Qu P; Zhao Y; Liu J; Zhao J; Kong B
Bioengineered; 2022 Jan; 13(1):1931-1941. PubMed ID: 35001804
[TBL] [Abstract][Full Text] [Related]
5. Pleiotrophin regulates the ductular reaction by controlling the migration of cells in liver progenitor niches.
Michelotti GA; Tucker A; Swiderska-Syn M; Machado MV; Choi SS; Kruger L; Soderblom E; Thompson JW; Mayer-Salman M; Himburg HA; Moylan CA; Guy CD; Garman KS; Premont RT; Chute JP; Diehl AM
Gut; 2016 Apr; 65(4):683-92. PubMed ID: 25596181
[TBL] [Abstract][Full Text] [Related]
6. Expression of receptor protein tyrosine phosphatase ζ is a risk factor for triple negative breast cancer relapse.
Fu F; Xiao XI; Zhang T; Zou Q; Chen Z; Pei L; Su J; Yi W
Biomed Rep; 2016 Feb; 4(2):167-172. PubMed ID: 26893832
[TBL] [Abstract][Full Text] [Related]
7. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
8. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
Yuan Z; Jiang H; Zhu X; Liu X; Li J
Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
[TBL] [Abstract][Full Text] [Related]
9. Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway.
Li T; Zhang Q; Zhang J; Yang G; Shao Z; Luo J; Fan M; Ni C; Wu Z; Hu X
BMC Cancer; 2014 Feb; 14():96. PubMed ID: 24529079
[TBL] [Abstract][Full Text] [Related]
10. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE.
Qiao J; Chen Y; Mi Y; Jin H; Wang L; Huang T; Li H; Song Y; Cao J; Wu B; Wang Q; Zou Z
Biochem Pharmacol; 2020 Oct; 180():114126. PubMed ID: 32603665
[TBL] [Abstract][Full Text] [Related]
11. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
12. CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer.
Chen W; Qin Y; Wang D; Zhou L; Liu Y; Chen S; Yin L; Xiao Y; Yao XH; Yang X; Ma W; Chen W; He X; Zhang L; Yang Q; Bian X; Shao ZM; Liu S
PLoS Biol; 2018 Jul; 16(7):e2005869. PubMed ID: 30052635
[TBL] [Abstract][Full Text] [Related]
13. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
[TBL] [Abstract][Full Text] [Related]
14. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
[TBL] [Abstract][Full Text] [Related]
15. Pleiotrophin and the Expression of Its Receptors during Development of the Human Cerebellar Cortex.
Santana-Bejarano MB; Grosso-Martínez PR; Puebla-Mora AG; Martínez-Silva MG; Nava-Villalba M; Márquez-Aguirre AL; Ortuño-Sahagún D; Godínez-Rubí M
Cells; 2023 Jun; 12(13):. PubMed ID: 37443767
[TBL] [Abstract][Full Text] [Related]
16. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
17. SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
Li K; Lin H; Liu A; Qiu C; Rao Z; Wang Z; Chen S; She X; Zhu S; Li P; Liu L; Wu Q; Wang G; Xu F; Li S
Cancer Lett; 2024 May; 590():216842. PubMed ID: 38582395
[TBL] [Abstract][Full Text] [Related]
18. Elevated IL-1β expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone.
Jeon M; Han J; Nam SJ; Lee JE; Kim S
Chem Biol Interact; 2016 Oct; 258():126-33. PubMed ID: 27567548
[TBL] [Abstract][Full Text] [Related]
19. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
20. Pleiotrophin suppression of receptor protein tyrosine phosphatase-β/ζ maintains the self-renewal competence of fetal human oligodendrocyte progenitor cells.
McClain CR; Sim FJ; Goldman SA
J Neurosci; 2012 Oct; 32(43):15066-75. PubMed ID: 23100427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
